Prosecution Insights
Last updated: April 19, 2026
Application No. 17/801,514

ALPHA-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Non-Final OA §112§DP
Filed
Aug 22, 2022
Examiner
LIEB, JEANETTE M
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jiangxi Normal University
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
97%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
623 granted / 780 resolved
+19.9% vs TC avg
Strong +17% interview lift
Without
With
+16.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
25 currently pending
Career history
805
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
37.4%
-2.6% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
15.5%
-24.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 780 resolved cases

Office Action

§112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Allowable Subject Matter Claims 1-3, 5-7, 9, 11, 12, 14, 15, 17-19 and 21-24 are free of the art because the amendment of 12/15/25 overcome the closest prior art Larkin et al., as discussed in the restriction requirement and is of record in the prosecution. However, applicants have amended formula I to remove the option of R1 being a C1 to C24 hydrocarbyl or heterocarbyl. As such, the claims are novel and unobvious over the prior art. Restriction/Election Claims 1-3, 12, 14 and 17-19 and 21-24 are allowable. The restriction requirement between groups 1-5, as set forth in the Office action mailed on 10/16/25 , has been reconsidered in view of the allowability of claims to the elected invention pursuant to MPEP § 821.04(a). The restriction requirement is hereby withdrawn as to any claim that requires all the limitations of an allowable claim. Specifically, the restriction requirement of 10/16/25 is withdrawn between groups 1-5 because all of the groups require formula I in the methods of synthesis. Claims 6, 7, 9, 11, 12, 14, 15, 17, 18, 19 and 21 are directed to methods for preparing amides having formula V, II and II, as well as a method for solid phase synthesis are no longer withdrawn from consideration because the claim(s) requires all the limitations of an allowable claim. In view of the above noted withdrawal of the restriction requirement, applicant is advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Note that the claims are free of the art, however some are objected to for minor informalities, but the dependent claims have been indicated as allowable above, if dependent on and object to claim. Objections Claim 6 is objected to because of the following informalities: there is a typographical error that leaves a space between the a and s before substituent. Appropriate correction is required. Claims 11 and 15 are objected to because of the following informalities: Each of these is an independent claim, but claim 11 begins with step B), without a step A) and claim 15 begins with step C) and D) without either steps A) or B). Appropriate correction is required. Claim 7 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections 35 USC 112 4th Paragraph The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 5 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 5 depends from the method of claims 11, but it is a product claim. The product claim cannot contain all of the subject matter of the method of making it. If claim 5 is intended to be a product by process claim, then the process must be recited in the same claim. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEANETTE M LIEB whose telephone number is (571)270-3490. The examiner can normally be reached M-F 10-7. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko Garyu can be reached on 571-270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEANETTE M LIEB/Primary Examiner, Art Unit 1654
Read full office action

Prosecution Timeline

Aug 22, 2022
Application Filed
May 05, 2023
Response after Non-Final Action
Jan 10, 2026
Non-Final Rejection — §112, §DP
Apr 02, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599647
PEPTIDE AMIDE COMPOSITION AND PREPARATION METHOD THEREFOR
2y 5m to grant Granted Apr 14, 2026
Patent 12583885
COMPOSITIONS OF HYBRID SUPPORTED LIPID BILAYERS AND METHODS FOR PRODUCING
2y 5m to grant Granted Mar 24, 2026
Patent 12569416
OIL-IN-WATER EMULSIFIED COSMETIC
2y 5m to grant Granted Mar 10, 2026
Patent 12571020
GENETICALLY ENGINEERED MICROORGANISMS THAT OVEREXPRESS MICROCIN-MGE AND METHODS OF PURIFICATION AND USE
2y 5m to grant Granted Mar 10, 2026
Patent 12559528
PPR PROTEIN CAUSING LESS AGGREGATION AND USE OF THE SAME
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
97%
With Interview (+16.8%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 780 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month